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Abstract: For development to proceed normally, animal eggs must undergo a maturation 
process that ultimately depends on phosphorylations of key regulatory proteins. To analyze 
the kinases that mediate these phosphorylations, eggs of marine nemertean worms have 
been treated with pharmacological modulators of intracellular signaling pathways and 
subsequently probed with immunoblots employing phospho-specific antibodies. This 
article both reviews such analyses and compares them with those conducted on mammals, 
while focusing on how egg maturation in nemerteans is affected by signaling pathways 
involving cAMP, mitogen-activated protein kinases, Src-family kinases, protein kinase C 
isotypes, AMP-activated kinase, and the Cdc2 kinase of maturation-promoting factor. 
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1. Introduction 
Animal eggs begin their development in ovaries as immature oocytes, with each oocyte possessing 
a large nucleus that is referred to as the “germinal vesicle”, or GV (Figure 1). In response to 
appropriate stimulation, immature oocytes undergo a complex maturation process that starts with the 
disassembly of the oocyte nucleus during a sequence called germinal vesicle breakdown (GVBD). 
Following such GVBD and subsequent stages of maturation, the oocyte becomes a mature egg that is 
capable of developing further once fertilization has been achieved. In most animals, GVBD precedes 
fertilization, whereas in a few cases, GVBD begins after fertilization has occurred [1]. However, 
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regardless of the timing of GVBD relative to fertilization, all eggs must eventually mature in order for 
subsequent development to proceed normally. Thus, as might be expected for such an essential step in 
animal development, the underlying mechanisms of egg maturation have been intensively analyzed.  
Figure 1. Disassembly of the oocyte nucleus (=germinal vesicle breakdown, GVBD) at the 
onset of egg maturation.  Immature oocytes from a marine nemertean worm possess an 
intact nucleus (=GV). After maturation is induced, each oocyte undergoes GVBD to 
become a mature egg. 
 
 
 
 
 
 
 
 
 
As a result of such analyses, egg maturation has been shown to involve various regulatory proteins, 
whose activities are often modulated by site-specific phosphorylations. Such phosphorylations in turn 
depend on upstream kinases that add phosphate groups to their protein targets and associated 
phosphatases that cause dephosphorylation, thereby providing a counterbalanced mechanism for 
modulating protein activity. In order to monitor these phosphorylations, early studies often utilized in 
vitro assays of individual kinases and targets that were purified from cells and incubated with 
radioactive phosphate to measure phosphate incorporations on a case-by-case basis. However, the 
advent of phospho-specific antibodies and their usage in conjunction with immunoblotting techniques 
have now provided an alternative method for assaying multiple phosphoproteins in total cell lysates.  
A major impetus for applying such methods to studies of egg maturation can be traced back to 
1971, when it was shown that the cytoplasm of maturing oocytes contains a “maturation-promoting 
factor” (MPF) that stimulates GVBD after being injected into immature oocytes [2]. Subsequent 
analyses have revealed that MPF is a heterodimer consisting of a regulatory protein called cyclin B 
plus a kinase component referred to as Cdc2. Moreover, such investigations have demonstrated that 
MPF’s activity can be either inhibited or stimulated by different types of phosphorylations   
(Figure 2)[3–7]. 
Since the discovery of MPF, cellular signaling pathways that ultimately regulate the 
phosphorylation of MPF have been investigated in various animals, particularly within mammals, 
where results obtained from such studies can have important veterinary and clinical applications. For 
example, mice represent an intensively analyzed mammalian model, while considerable work has also 
been conducted on egg maturation in other rodents such as rats, as well as in primates and 
domesticated mammals, including cows, pigs, and horses. However, mammalian eggs are not 
optimally suited for all analyses. For example, compared to most other animals, relatively low 
numbers of eggs can be obtained at any one time from a fertile mammal. Moreover, given that 
intraovarian oocytes of mammals develop within complex follicles that are subject to input from 
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multiple sources, it can be difficult to fully replicate the in vivo cues that mediate egg maturation in 
mammals. Similarly, the external layers of residual follicle cells (=“cumulus cells”) that surround 
mammalian oocytes after they have been ovulated from the ovary can in some cases complicate 
interpretation of experimental results. 
Figure 2. Differing phosphorylation status affecting MPF activity and egg maturation. 
Blots showing phosphorylation status of the ~32 kD Cdc2 kinase of MPF in oocytes of a 
marine nemertean worm: (A) Active MPF, which has phosphorylated T161 and   
non-phosphorylated Y15 on Cdc2, is at low levels in immature oocytes [before treatment 
(before) or after 2 hr in calcium-free seawater (cafsw)] vs. at high levels in mature eggs 
[after 2 hr in seawater (SW) or SW + 10 μM of the cAMP elevator forskolin (for)];   
(B) Inactive MPF (high p-Y15; low p-T161) is high in immature oocytes and low in mature 
eggs (see Section 2.6 for more details). 
 
 
 
 
 
 
As an alternative to analyzing egg maturation in mammals, various non-mammalian animals, 
including marine invertebrates, have also been investigated. For example, egg maturation has been 
studied in marine worms belonging to the phylum Nemertea [8]. Such nemerteans (or “ribbon worms”) 
typically have separate sexes, and in the case of a ripe female, numerous ovaries are present along the 
length of the body. During the breeding season that usually occurs in spring or summer, most 
nemerteans discharge their gametes directly into the sea [9]. Moreover, unlike in mammals, 
nemerteans characteristically lack follicle cells during intraovarian stages of egg development and 
around their post-spawned eggs [10]. Thus, small pieces of gravid nemerteans are capable of yielding 
hundreds to thousands of follicle-free oocytes that start GVBD ~15–30 min after treatment with 
seawater (SW). Conversely, nemertean oocytes can be kept immature in calcium-free seawater 
(CaFSW) before being immersed in SW to overcome the inhibitory effects of CaFSW [11]. Moreover, 
not only is GVBD stimulated by replacing CaFSW with SW, but agents that elevate intraoocytic levels 
of cyclic 3’,5’-adenosine monophosphate (cAMP) also cause maturation when added directly to 
CaFSW.  
Exactly why nemertean GVBD is triggered by SW and blocked by CaFSW has not been fully 
elucidated, but supplementing artificial seawaters with Ca
2+ only partially restores GVBD, indicating 
that natural SW contains additional GVBD-inducing substance(s) other than just Ca
2+ itself [11]. 
Moreover, although it is possible that SW-stimulated oocytes also undergo some sort of rise in cAMP 
during GVBD, the precise patterns of these potential cAMP elevations and/or their mediating 
pathways must differ following treatment with SW vs. cAMP elevators. Such a conclusion is based on 
the fact that various kinds of drugs block SW-induced GVBD, whereas simply combining these drugs 
in SW with cAMP elevators fully restores GVBD, thereby demonstrating that non-identical   
GVBD-inducing mechanisms are triggered by SW vs. cAMP elevators (Figure 3). Accordingly, the 
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multiple modes of achieving GVBD indicated by such cAMP-induced rescues provide a means for 
assessing whether the blockages of GVBD observed in SW solutions of pharmacological agents are 
just due to oocyte morbidity or to a drug effect that can be reversed by alternative signals mediated by 
cAMP elevators. 
Figure 3. Differing modes of seawater- vs. cAMP-induced egg maturation in nemerteans. 
When added to seawater (SW), various drugs (e.g., tyrphostin inhibitors of tyrosine kinases 
[AG82, AG112, AG556 at 50–100 μM]) significantly reduce egg maturation (=blue bars) 
compared to controls in SW alone (control GVBD in SW=95.9 ± 7%; N = 56), whereas  
co-treatments of tyrphostins plus cAMP elevators (=green bars) in SW restore GVBD, 
indicating SW and cAMP elevators utilize different maturation-inducing pathways. 
 
 
 
 
 
 
 
 
 
 
As opposed to numerous relatively recent synopses that are available for mammalian egg 
maturation [12–15], this review summarizes for the first time previous studies on SW- vs.  
cAMP-induced maturation in nemertean eggs. In particular, the roles played by protein 
phosphorylations in maturing nemertean eggs are covered, while focusing on signaling pathways 
involving cAMP, mitogen-activated protein kinases (MAPKs), Src-family kinases (SFKs), protein 
kinase C isotypes (PKCs), AMP-activated kinase (AMPK), and MPF. In addition, studies of nemertean 
egg maturation are also briefly compared and contrasted with results previously reported for mammals 
in order to synthesize common and divergent patterns of egg maturation in these two distantly related 
groups of animals. In so doing, such comparisons relate to an overall goal of this special issue that is 
aimed at elucidating the functional significance of proteins expressed by various marine organisms. 
2. Results and Discussion 
2.1. Elevations in intraoocytic cAMP trigger GVBD in nemerteans as opposed to generally inhibiting 
GVBD in mammals 
In nemerteans, pre-GVBD increases in cAMP have been observed by confocal microscopy in 
maturing oocytes that had been microinjected with a vital probe for tracking cAMP, and based on 
several lines of evidence, such intraoocytic cAMP elevations serve to trigger egg maturation [16]. For 
example, GVBD in nemerteans can be elicited by a variety of cAMP-elevating drugs with diverse 
modes of action, including: (1) membrane-permeable cAMP; (2) forskolin, which stimulates the 
cAMP-synthesizing activities of adenylate cyclases (ACs); (3) such phosphodiesterase (PDE) 
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inhibitors as IBMX and Ro-20-1724 that block the degradation of cAMP; and (4) serotonin (“5-HT”), 
which may act as both an AC stimulator and a PDE inhibitor [16]. In addition, inhibitors of the main 
downstream target of cAMP, protein kinase A (PKA), block GVBD in nemerteans [16], collectively 
indicating that cAMP signaling stimulates maturation in nemertean eggs. 
Conversely, based on various studies, GVBD in mammals tends to be blocked by elevations in 
intraoocytic cAMP, and as opposed to its antagonistic effect on GVBD in nemerteans, inhibiting the 
cAMP target PKA can trigger mammalian egg maturation [17–23]. Such increased levels of cAMP in 
immature mammalian oocytes are mediated via signals received from surrounding follicle cells   
[24–27]. Accordingly, mammalian oocytes that are removed from their follicles can undergo a decline 
in cAMP followed by the onset of GVBD. Thus, to prevent denuded oocytes from initiating such 
“spontaneous maturation”, mammalian oocytes are typically incubated continually in various   
cAMP-elevating drugs to maintain elevated cAMP levels and an inhibition of GVBD for prolonged 
periods. However, a variation on the inhibitory effects of cAMP has been documented with data 
showing that a short elevation in intraoocytic cAMP actually leads to the stimulation, rather than 
inhibition, of GVBD in mice, as such a cAMP pulse causes a GVBD-stimulating increase in AMPK 
activity, which normally does not occur in immature oocytes subjected to prolonged elevations in 
cAMP [28]. 
In any case, although the exact reasons why intraoocytic cAMP elevations tend to generate opposite 
results in mammalian vs. nemertean eggs have not been determined, it is clear that nemerteans are not 
the only animals to differ from mammals, as several other marine invertebrates are also known to 
undergo cAMP-induced GVBD [29–33]. Accordingly, compared to mammals, nemertean eggs may 
react differently to cAMP owing to alternative kinds of upstream modulators and downstream targets 
of cAMP (e.g., PDEs, PKAs, AMPKs) and/or to differing subcellular localizations of key maturation 
regulators [34]. Moreover, such differences in turn may somehow relate to the presence of follicle cells 
in mammals and their absence in nemerteans, given that in nemerteans and the other marine 
invertebrates where stimulation of GVBD by cAMP has been reported to occur, follicle cells are either 
lacking or apparently not as well connected to immature oocytes as in mammals [35,36].  
2.2. ERK 1/2 MAPKs are activated before, but not required for, GVBD in nemerteans 
Mitogen-activated protein kinases (MAPKs) constitute a diverse family of Ser/Thr kinases that can 
play key roles in regulating cell division [37–40]. For various eggs, MAPKs of the type called ERK 
1/2 (extracellular signal regulated kinases 1/2, =“MAPKs 3/1”, or simply MAPK hereafter) represent 
the most intensively analyzed forms of these kinases. Accordingly, in nemerteans, MAPK activity has 
been shown to be low in immature oocytes, based on immunoblots using a widely employed   
phospho-specific antibody that recognizes the dually phosphorylated and thereby activated form of 
MAPK (Figure 4A)[41–44]. Conversely, in response to stimulation by either SW or cAMP elevators, 
MAPK becomes activated prior to GVBD and typically remains elevated post-GVBD as such mature 
eggs become arrested at metaphase I of meiosis [41–44]. Similarly, a maturation-induced increase in 
MAPK activity has also been verified in kinase assays using a known target of active MAPK [41]. 
To analyze potential upstream regulators of MAPK activation during nemertean egg maturation, 
immature oocytes have been incubated in SW solutions containing inactivators of Raf-1, a MAPK Mar. Drugs 2010, 8                 
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kinase kinase (MAPKKK). Such treatments specifically block SW-induced MAPK activation and 
GVBD [43]. Conversely, adding cAMP elevators restores both MAPK activity and GVBD [43]. 
Similarly, several kinds of tyrphostin-type inhibitors of tyrosine kinases also block MAPK activation 
and GVBD in response to SW, whereas both of these processes are re-established by co-treatment with 
cAMP elevators [35]. Collectively, these findings suggest that MAPK activation and GVBD during 
SW stimulation depend on Raf-1 activity and some as-of-yet undetermined tyrosine kinase. 
Alternatively, cAMP signaling can apparently activate MAPK and trigger GVBD via a   
Raf-1-independent mechanism that does not involve the activity of tyrosine kinases or other substrates 
targeted by the tested tyrphostins. 
Figure 4. Protein phosphorylations in immature oocytes vs. mature eggs of nemerteans. 
Blots probed with phospho-specific antibodies to track active forms of: (A) ERK 1/2 
mitogen-activated protein kinase (MAPK), (B) Src family kinases (SFK); (C), Protein 
kinase C related kinase (PRK), or (D) AMP-activated kinase (AMPK). 5ht = serotonin; 
cafsw = calcium-free seawater; for = forskolin; pp2 = SFK inhibitor; sw = seawater. 
 
 
 
 
 
 
 
Moreover, these results suggest that nemertean egg maturation is normally associated with an 
increase in MAPK activity. However, to determine if in fact MAPK is actually required for GVBD, 
immature oocytes have been incubated in several inhibitors of MAPK kinase (MAPKK) prior to 
stimulation by SW or cAMP elevators. In response to the MAPKK inhibitors PD98059 and CI1040, 
MAPK activation remains downregulated during either SW or cAMP stimulation, and yet such 
specimens consistently undergo GVBD [44]. Similarly, the MAPKK antagonist U0126 also fails to 
block cAMP-induced GVBD while inhibiting MAPK activity, and some U0126-treated oocytes still 
continue to mature in SW. However, in other oocyte batches, SW-induced GVBD is indeed lower in 
the presence of U0126 [42–44]. Nevertheless, other drugs that inactivate MAPK (e.g., the Src 
inhibitors PP2 and SU6656: see next section) also allow both SW- and cAMP-induced GVBD in the 
absence of marked MAPK activation [43]. Such findings demonstrate that although tests utilizing  
Raf-1 and tyrosine kinase inhibitors suggest MAPK is required for SW-induced GVBD, the fact that 
oocytes still undergo GVBD without displaying marked MAPK activity when treated with MAPKK or 
Src antagonists reveals that maturation can occur via a MAPK-independent mechanism. Accordingly, 
the blockage of SW-induced GVBD by Raf-1, tyrosine kinase inhibitors, and U0126 is apparently due 
to one or more drug effects other than just MAPK inhibition.  
Aside from analyses of GVBD prior to insemination, additional investigations have revealed that 
during fertilizations in the presence of MAPK inhibitors, polar bodies are still formed as eggs continue 
with the first cell cycle [44]. Thus, as with GVBD, at least some post-GVBD processes that occur 
during egg maturation in nemerteans can proceed without pronounced MAPK activation. 
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As for mammals, the potential roles played by intraoocytic MAPK activation in maturing eggs 
appear a bit more varied, as there is evidence indicating that an increase in MAPK occurs within 
oocytes of some species prior to GVBD and may be required for initiating maturation [14,45,46]. 
Conversely, in other mammals, MAPK does not become activated in oocytes until after GVBD is 
elicited and is thus not required for GVBD [14,45,46]. Nevertheless, in spite of these differences, 
MAPK must be activated in follicle cells surrounding mammalian oocytes in order for egg maturation 
to proceed properly [47,48]. Moreover, as reviewed elsewhere [14,45,46], intraoocytic activation of 
MAPK can certainly play important roles during post-GVBD stages of mammalian egg maturation, 
including the proper formation of meiotic spindles and polar bodies. 
2.3. Src-family kinase activation does not appear to be needed for GVBD in nemerteans 
Src-family kinases (SFKs) are ~52–62 kD non-receptor tyrosine kinases that include such examples 
as Src, which is the first SFK member documented to upregulate egg maturation [49]. To determine if 
SFKs stimulate GVBD in nemertean oocytes, immature specimens have been incubated in SW 
solutions of the SFK inhibitors PP2 and SU6656. Such treatments fail to block GVBD, even though 
the drugs are effective in deactivating MAPK, and at least in the case of PP2, can reduce SFK 
activation as judged by blots probed with a phospho-specfic antibody to active SFKs (Figure 4B)[50]. 
Moreover, not only does SFK activity fail to exhibit a marked increase in mature eggs vs. immature 
oocytes, treating CaFSW-incubated immature oocytes with SFK inhibitors actually causes a slight 
increase in GVBD over baseline levels in CaFSW alone (unpubl. obsv.). Collectively, such findings 
suggest that SFKs are not required for nemertean GVBD, and in fact, can serve to inhibit it. 
Similarly, in one study of mouse oocytes, inactivation of SFK by the pharmacological inhibitor 
SKI606 also fails to prevent GVBD and actually accelerates the onset of maturation [51]. 
Alternatively, another investigation reports a blockage of GVBD following the use of PP2 to 
downregulate SFK activity in mouse oocytes [52]. Although the reasons for this discrepancy have not 
been determined, such variable effects may be due to differing specificities of action for the two SFK 
inhibitors and/or to variations in the strains of mice and the formulations of culture media used in these 
experiments [51]. In any case, data obtained for the roles played by SFKs during subsequent stages of 
mammalian egg maturation consistently demonstrate that SFK activity is required for post-GVBD 
progression to Metaphase II (Met II) arrest as well as for proper resumption of meiosis following Met 
II arrest [51,53–56].  
2.4. Inhibitors of atypical PKCs and PKC-related kinases (PRKs) block SW-, but not cAMP-induced, 
GVBD in nemerteans 
Eukaryotic cells can express 11 isotypes of protein kinase C (PKC) that are usually assigned to 
three classes—conventional, novel, and atypical [57–59]. To attain full activity, conventional PKCs 
(α,βI,βII,γ) require calcium ions (Ca
2+) and diacylglycerol (DAG)[or a DAG analog such as   
12-O-tetradecanoylphorbol 13-acetate (TPA)]. Novel isotypes (δ,ε,μ,η,θ), on the other hand, are 
activated by DAG but not Ca
2+, and atypical PKCs (ζ, λ/ι) are insensitive to both Ca
2+ and the type of 
DAG that stimulates conventional/novel isotypes [57–59]. In spite of such differences, PKCs share Mar. Drugs 2010, 8                 
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amino acid sequences that are typically phosphorylated in a conserved fashion during kinase activation 
and can thus be monitored via phospho-specific antibodies as a means of assessing PKC activity [36].  
Based on such antibodies, nemertean oocytes activate one or more PKCs during maturation induced 
by SW or cAMP-elevating drugs [36]. Accordingly, in SW-stimulated oocytes, GVBD is inhibited by 
broadly acting PKC antagonists such as bisindoylmaleimide (BIM)-I or BIM-IX, whereas co-treatment 
with SW solutions of BIM-I or BIM-IX plus a cAMP elevator restores GVBD, suggesting that SW-, 
but not cAMP-induced GVBD depends on PKC activation [36]. In tests to determine which specific 
PKC regulates GVBD, immunoblots fail to provide evidence for TPA-sensitive conventional or novel 
PKCs [36]. Moreover, inhibitors of such PKCs do not prevent SW-induced GVBD, and instead of 
stimulating GVBD, as would be expected if TPA-sensitive PKCs triggered maturation, TPA itself 
actually downregulates GVBD [36]. Alternatively, maturing oocytes possess phosphorylated forms of 
TPA-insensitive atypical isotypes as well as a PKC-related kinase (PRK), which would also 
presumably be insensitive to TPA (Figure 4C)[36]. Accordingly, inhibitors of atypical PKC/PRK 
signaling block SW- but not cAMP-induced GVBD [36], collectively suggesting that SW-, but not 
cAMP-induced, GVBD requires activation of an atypical PKC and/or PRK and that 
conventional/novel PKC activity may inhibit GVBD. 
After GVBD is completed in nemerteans, a positive feedback loop is apparently established 
between PKC and MAPK signaling pathways such that MAPK and one or more unidentified   
~80–95 kD conventional/novel PKCs stimulate each other and thereby keep the activities of both kinds 
of kinases elevated within metaphase-I-arrested mature eggs [44]. Accordingly, following fertilization 
of these eggs, such positive feedback is uncoupled, as both kinase types normally decrease their 
activities [44]. Moreover, for fertilizations conducted in the presence of BIM-I to inhibit PKCs, sperm 
incorporation and polar body formation still occur, but first cleavage is blocked, suggesting that 
although certain aspects of post-fertilization maturation can continue in the absence of PKC activation, 
full progression through the first cell cycle requires the activity of one or more as-of-yet unidentified 
PKC isotypes [44].  
As for mammals, whether PKC up- or downregulates egg maturation appears to vary depending on 
the species examined and/or the experimental design used [60]. In mice, at least some of this 
variability could be due to the fact that PKC activation in surrounding follicle cells typically triggers 
GVBD, whereas stimulating PKC within immature oocytes tends to inhibit GVBD [60]. Moreover, 
intraoocytic PKC activity may not always have the same effect on GVBD in mice, as some PKC 
isotypes can either down- or upregulate GVBD depending on the timing of their activation and their 
localization relative to the nuclear vs. cytoplasmic compartments of the oocyte [61]. In any case, as 
opposed to the case in nemerteans where SW-induced GVBD apparently requires the activity of 
atypical PKC and/or PRK, most studies using pharmacological modulators of PKC indicate that 
GVBD in rodent eggs is inhibited by intraoocytic PKC activations that in turn appear to involve 
conventional isotypes [60–66]. Similarly, the continued production of polar bodies following 
fertilization of BIM-I-treated nemertean oocytes contrasts with the blockage of polar body formation 
in similarly treated mammalian oocytes that has previously been reported in many [67–69] but not  
all [70] analyses of PKC signaling. In any case, in order to clarify further the functions of PKC 
isotypes during egg maturation, pharmacological modulators of PKC signaling need to be used 
judiciously owing to potential problems associated with such drugs, and wherever possible data Mar. Drugs 2010, 8                 
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obtained with these modulators should be supplemented with results using genetic knockouts and RNA 
interference strategies [59]. 
2.5. Stimulators of AMP-activated kinase block SW- but not cAMP-induced GVBD in nemerteans  
In eukaryotes, decreased nutrient availability and various other stresses can increase intracellular 
AMP:ATP ratios and thereby stimulate AMP-activated kinase (AMPK), a highly conserved regulator 
of energy states and cell cycle progression [71–73]. To test the possible roles played by AMPK 
activation during egg maturation in nemerteans, oocytes have been frozen at increasing times 
following stimulation with either SW or cAMP elevators before being subjected to immunoblotting 
with phospho-specific antibodies to AMPK and its downstream target acetyl CoA carboxylase [74]. 
Such studies reveal that AMPK activity is normally high in immature oocytes and subsequently 
reduced during either SW- or cAMP-induced GVBD (Figure 4D). Accordingly, adding various AMPK 
agonists to SW maintains AMPK activity and blocks SW-induced GVBD [74]. Conversely, co-treating 
oocytes with SW solutions of such AMPK agonists plus cAMP elevators restores AMPK deactivation 
and allows GVBD to occur [74]. Collectively, these findings indicate that active AMPK normally 
blocks nemertean GVBD and that cAMP elevators can downregulate AMPK via a mechanism that is 
independent of the AMPK-deactivating pathway(s) elicited by SW.  
In mice, AMPK activation triggers GVBD in either cumulus-enclosed or denuded oocytes [75–77]. 
Conversely, studies of cows and pigs have shown that activating AMPK in cumulus-enclosed oocytes 
can block GVBD [78–80]. Thus, the effects of AMPK on mammalian egg maturation may vary, 
depending on the species analyzed, although, at least in cows, further analyses are needed to determine 
if such inhibitory effects of AMPK activation are due to direct responses within the oocyte itself or to 
AMPK-mediated signals transmitted from surrounding follicle cells to the oocyte [81]. 
2.6. Egg maturation in nemerteans requires activation of pre-MPF following stimulation by either SW 
or cAMP elevators 
Although there are a few exceptions where GVBD can be triggered by RINGO/SPDY-mediated 
stimulation of Cdc2 or perhaps by other regulators [82,83], the initiation of GVBD in animals 
generally requires activation of MPF itself. In order to activate MPF in oocytes of the frog Xenopus 
and many other animals, the Cdc2 kinase of inactive “pre-MPF” (=cyclin B bound to inactive Cdc2) 
needs to become properly phosphorylated (Figure 2). Thus, as pre-MPF becomes activated, the T161 
residue of Cdc2 remains phosphorylated by cyclin-dependent kinase activating kinase (CAK), while an 
inhibitory phosphate placed on Y15 of Cdc2 by Myt-1/Wee-1 kinases is ultimately removed by one or 
more isotypes of a phosphatase called Cdc25 [4]. Alternatively, in some fish and non-Xenopus 
amphibians, MPF activation involves the de novo synthesis of cyclin B and its binding to a form of 
Cdc2 that is properly phosphorylated at just T161 [7,84]. 
To determine if nemertean GVBD depends on a dual-phosphorylation mode of activating pre-MPF, 
immature oocytes have been incubated with various MPF inhibitors and subsequently stimulated with 
either SW or cAMP elevators. In controls lacking the MPF inhibitors, maturing eggs show a rise in 
T161 phosphorylation and a decrease in Y15 phosphorylation (Figure 2)[43]. Similarly, MPF 
inhibitors serve to deactivate MPF by reducing the stimulatory T161 phosphorylation and by Mar. Drugs 2010, 8                 
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maintaining relatively high levels of the inhibitory Y15 phosphorylation. Moreover, during both SW 
and cAMP stimulation, GVBD is blocked by MPF inhibitors. However, compared to SW-incubated 
oocytess, higher doses of MPF inhibitors are needed for preventing cAMP-induced GVBD, and such 
drug treatments usually allow a greater amount of MAPK activation in the presence of cAMP elevators 
[43], collectively suggesting that although both modes of inducing maturation require MPF activity, 
alternative pathways for activating pre-MPF may be utilized in SW- vs. cAMP-induced GVBD. 
Accordingly, given that inhibitors of protein tyrosine phosphatases (PTPs) can inhibit SW- but not 
cAMP-induced GVBD [43], more specific blockers of the dual-specificity phosphatase Cdc25 have 
been tested and also found to prevent SW-induced GVBD. Conversely, such blockage is routinely 
rescued by cAMP elevators, suggesting that MPF activation in SW requires Cdc25 activity, whereas 
cAMP signaling is able to promote MPF activation via an alternative pathway of downregulating Y15 
phosphorylation. Conversely, several inhibitors of phosphatases that dephosphorylate Ser-Thr 
residues, including the phosphatase inhibitor okadaic acid (OA), fail either to block GVBD or to 
trigger maturation in CaFSW-incubated immature oocytes [43], suggesting that pathways involved in 
nemertean GVBD may not be fully dependent upon phosphatases affected by these inhibitors. 
In mammals, various studies have confirmed that MPF activation is generally required for GVBD. 
Moreover, such MPF activation can depend on a dual-phosphorylation mode of pre-MPF conversion 
into active MPF involving maintenance of T161 phosphorylation and depletion of Y15 
phosphorylation [4,14]. Accordingly, as with nemerteans, regulation of Cdc25 activity can play a 
crucial role during MPF activation in mammalian oocytes [85,86]. However, unlike what has been 
reported for nemerteans where the Ser/Thr phosphatase inhibitor OA fails to block or trigger GVBD, 
mammalian oocytes can undergo maturation in response to OA [87,88]. 
3. Conclusions 
Based on data reviewed above, nemertean eggs are triggered to mature via multiple intracellular 
pathways that are set in motion by either seawater stimulation or by elevators of cAMP (Figure 5).  
Figure 5. Effects of inhibitors on egg maturation induced by seawater vs. cAMP elevators 
in marine nemertean worms  (for further clarification and explanation of abbreviations,   
see text). 
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In several important ways (e.g., cAMP and AMPK signaling), what triggers GVBD in nemerteans 
can have an opposite effect on mammalian egg maturation, and vice versa (Table 1).  
Table 1. Summary of effects of various signals on GVBD in nemertean vs. mammalian eggs. 
Signal regulating egg maturation:  Positive (+) or negative (-) effect of signal on GVBD 
in nemerteans [refs] (notes): in mammals [refs] (notes): 
Intraoocytic cAMP elevation  + [16,35,36,43]   - [17–27] 
ERK 1/2 MAPK activation  + [41–44] (a)  + [14,45–48] (a,b) 
Src family kinase activation  - [50]  - [51] or + [52] 
Protein kinase C activation  + [36,44] [c]  - [60–66] (d) 
Intraoocytic AMP kinase activation  - [74]  + [75–77] (e) 
Increased Cdc2 kinase activity via 
conversion of pre-MPF into MPF 
+ [43]  + [4,14] 
(a)  Although intraoocytic ERK 1/2 MAPK activation may serve to stimulate GVBD, such activity 
is generally not required for GVBD to occur. 
(b) ERK 1/2 MAPK activation in follicle cells is required for GVBD. 
(c)  Atypical PKCs and/or PKC-related kinase are required for GVBD; conventional/novel PKCs 
may inhibit GVBD. 
(d) Activation of intraoocytic PKCs tends to inhibit GVBD, although the timing and precise 
localization of such activation may also cause stimulation of GVBD [61]. 
(e)  Intraoocytic AMPK activation stimulates GVBD in mice; activation of AMPK in follicles of 
pigs and cows can inhibit GVBD [78–81]. 
However, although nemertean and mammalian oocytes can utilize similar intraoocytic signaling 
components to modulate GVBD in opposing fashions, the follicular compartment of mammals also 
interacts with intraoocytic signals, thereby forming an integrated system in mammals. Accordingly, it 
is important to compare signaling within the entire mammalian follicle to that in follicle-free 
nemertean oocytes. When considered in this way, signaling pathways in nemertean oocytes often 
resemble those in mammalian follicle cells, whereas the intraoocytic pathways of mammals can exhibit 
opposite effects to either nemertean oocytes or surrounding follicle cells. 
In any case, it is clear that further comparative analyses are needed to elucidate both common 
themes and diverging patterns of egg maturation in nemerteans vs. mammals. Such studies should take 
advantage of the specific benefits of using these types of eggs (e.g., sequenced genomes and available 
genetic knockouts for mammals vs. ready supply of follicle-free nemertean oocytes that because of 
their multiple modes of triggering maturation provide built-in controls for pharmacological analyses). 
Collectively, such investigations will hopefully supplement those reviewed here and thereby help to 
clarify how various phosphoproteins and other regulatory molecules expressed by such marine 
organisms as nemertean worms can control the same fundamental process of egg maturation that we 
and other mammals must successfully complete in order to develop properly.  
4. Experimental 
Eggs were typically collected from an undescribed species of the nemertean Cerebratulus during 
summers on San Juan Island, WA, USA. Alternatively, additional analyses were also carried out with Mar. Drugs 2010, 8                 
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eggs obtained from other San Juan Island nemerteans [10] or from Cerebratulus lacteus that was 
purchased from the Animal Supply Department of the Marine Biology Laboratory (Woods Hole, MA) 
[89]. After removal from ovaries, immature oocytes were routinely pre-incubated in ice-cold   
calcium-free seawater (CaFSW) for 1.5–2.5 hr to reduce spontaneous GVBD [90,91]. Oocytes were 
then dejellied via a 150-μm Nitex filter to enhance oocyte pelleting and transferred to SW- or CaFSW-
solutions maintained at typical ambient SW temperatures (~12–14 
oC) with or without added drugs 
typically purchased from: Enzo Life Sciences (Plymouth Meeting, PA); LC Labs (Woburn, MA); 
Sigma (St. Louis, MO); or Tocris (Ellisville, MO). To determine optimal concentrations of drugs to be 
used, dose-response curves were generated for GVBD, and from these curves, doses occurring 
between the ED50 (effective dose for 50% of the oocytes) and the maximally effective concentrations 
were routinely adopted in order to achieve a trade-off between increased effectiveness and reduced 
likelihood of off-target effects [92]. For immunoblotting, total cell lysates were obtained from liquid-
nitrogen-frozen oocytes using lysis buffer containing inhibitors of proteases and phosphatases, and 
after running such lysates on 4%/10% SDS PAGE gels that were cast with BioRad acrylamide   
(#161-0158), the separated proteins were transferred to PVDF membranes at 100V for 60–75 min and 
subsequently probed with primary antibodies from Cell Signaling Technology (Danvers, MA) or 
Millipore (Billerica, MA)[35,41–45,74]. Densitometry of background-subtracted bands was routinely 
performed on at least three blots from two or more females, and in cases with ambiguous results, 
statistical analyses were conducted as described previously [41–45].  
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